title: [18 months long-term analysis of effectiveness, safety and tolerance of sumatriptan s.c. in acute therapy of migraine attacks].
abstract: The aim of the open prospective study was to investigate the efficacy, safety and tolerability of subcutaneous sumatriptan in acute migraine treatment. Patient self-treatment was monitored over a time period of 6-18 months with 6 mg of sumatriptan administered subcutaneously by an autoinjector. In total, 2,263 patients participated in the study. Headache intensity was documented by the patient in a headache diary before and 1 and 2 h after application. During the study period from October 1991 to June 1993, 43,691 migraine attacks were investigated. Treatment with sumatriptan was efficient in 89.5% of the attacks. Headache relief was achieved in 71%. Headache reoccurred in 22.7% of the attacks, and therefore a second injection was administered. An intraindividual treatment efficacy of 80-100% was achieved in 82.9% of the patients. During long-term treatment the ratio of effective treatment and headache frequency was constant; 4.9% of the patients withdrew from the study because of adverse events and because they felt the treatment was not effective. A total of 44.5% of the patients reported adverse events that were serious in 1.7%. Subcutaneous self-treatment with sumatriptan in the acute treatment of migraine is effective and well tolerated by the patients.
authors.affiliation: Klinik für Neurologie der Christian-Albrechts-Universität, Kiel.
authors.forename: H
authors.initials: H
authors.lastname: Göbel
authors.forename: H
authors.initials: H
authors.lastname: Stolze
authors.forename: A
authors.initials: A
authors.lastname: Heinze
authors.forename: M
authors.initials: M
authors.lastname: Dworschak
authors.forename: D
authors.initials: D
authors.lastname: Heuss
authors.forename: K
authors.initials: K
authors.lastname: Christiani
authors.forename: V
authors.initials: V
authors.lastname: Lindner
mesh_terms: D000328:Adult; D004361:Drug Tolerance; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007279:Injections, Subcutaneous; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000188:drug therapy*; D010147:Pain Measurement; D011446:Prospective Studies; D012008:Recurrence; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage* / Q000009:adverse effects; D018170:Sumatriptan / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D017366:Serotonin Receptor Agonists; D014665:Vasodilator Agents; D018170:Sumatriptan
vernacular_title: Achtzehnmonatige Langzeitanalyse der Wirksamkeit, Sicherheit und Verträglichkeit von Sumatriptan s.c. in der Akuttherapie von Migräneanfällen.